Magnetic resonance imaging (MRI) is better than systematic biopsies for diagnosing prostate cancer; thereby reducing redundant biopsies, a Cochrane review and meta-analysis revealed. However, the findings are practice-changing, coauthor Dr. Ivo Schoots of Erasmus University Medical Center Rotterdam told Reuters Health by email. “Therfore recommending upfront MRI in all men suspected to have prostate cancer…
Nivolumab showed durable antitumor activity among patients with metastatic bladder cancer; both alone and combined with ipilimumab, according to extended follow-up from the CheckMate 032 study. Nivolumab (Opdivo, Bristol-Myers Squibb) combined with high-dose ipilimumab (Yervoy, Bristol-Myers Squibb); yielded the greatest antitumor activity of all regimens evaluated and had a tolerable safety profile. “However, the approval…
In the modern era of advanced imaging and genomics testing; the digital rectal exam (DRE) is still an “important” and clinically relevant prognostic test for prostate cancer;conclude the authors of a new observational study. The role of the DRE, which is a “historic” method of staging the disease; has been “uncertain” in recent years, acknowledge…
A combination of enzalutamide and androgen deprivation therapy (ADT) significantly reduced; the risk of metastatic prostate cancer, according to the results of clinical trial led by Duke Cancer Institute. The findings, published in the Journal of Clinical Oncology, the product of a multi-institutional study called ARCHES; which evaluated the efficacy and safety of enzalutamide, an…
Cancer researchers at the University of Virginia School of Medicine, identified a key to controlling the growth and progression of prostate cancer; the second most common cancer in men. The researchers dubbed this key “HULLK,” and they believe it can be use to target and stop the progression of a cancer that kills more than…
A fast MRI protocol can accurately identify prostate cancer in biopsy-naive men; at lower cost with minimally increased biopsy rates, researchers from the Netherlands report. Fast MRI has suggested; as a means of reducing examination time and cost while retaining sufficient diagnostic accuracy; to rule out high-grade prostate cancer in biopsy-naive men. Multiparametric prostate magnetic…
In patients with metastatic bladder cancer marked by mutations in the FGFR3 gene; treatment with the FGFR inhibitor erdaftinib resulted in a 40% overall response rate (ORR) and was well-tolerated. The oral targeted therapy also achieved a 59% ORR in patients for whom immunotherapy had previously failed, indicating this may be a viable option for…
These new ‘search-and-destroy’ treatments are starting to show promise even in men with prostate cancer for whom targeted treatments and chemotherapies have stopped working but not all patients respond. In the new study, scientists at The Institute of Cancer Research, London, found that testing men for faults in DNA repair gene; in their tumours could…
Women who are suspected with a urinary tract infection will be able to access fast-track testing; and treatment without seeing a GP as part of a ground-breaking NHS England pilot scheme trialed in 38 ‘Pharmacy First’ branches across Nottinghamshire and Derbyshire. Instead of waiting for a GP appointment; women will be offered a Dip UTI…
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement; from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC); in the updated Essential Medicines List. However, the WHO’s Essential Medicines List is a core guidance document that helps countries prioritize…
This non-invasive diagnostic method could help detect the disease in its earliest stages with a small urine sample. A team from the Polytechnic University of Valencia (UPV), the La Fe Health Research Institute (IIS-La Fe); and the Centre for Biomedic Research in the fields of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), dependant of the Carlos III…
The antibacterial drug product Recarbrio (imipenem, cilastatin, and relebactam) has approve to treat complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) in adults, the U.S. Food and Drug Administration announced. “The FDA remains focus on facilitating the development of safe; and effective new antibacterial drugs to give patients more options to fight serious…